Earnings Data
Report Date
Aug 04, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.11Last Year’s EPS
-0.13Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a mixed but constructive view: top-line growth (total revenue +8%, clinic revenue +15%), improved profitability trends (narrower net loss and $2.0M adjusted EBITDA improvement), and meaningful operational initiatives (cost savings, go-to-market pilots, payer/regulatory tailwinds). Offsetting these positives are ongoing challenges including NeuroStar treatment revenue declines, gross margin contraction, a materially reduced cash balance ($19.0M vs $34.1M at year-end), continued GAAP losses and a near-term projected operating cash burn for the year. Management emphasized discipline, cash-flow focus, and pilots to expand reach — signaling a path to stabilization but with execution and liquidity risks to manage in the near term.Company Guidance
Total Revenue Growth
Total revenue of $34.5 million in Q1 2026, an increase of 8% year-over-year from $32.0 million in Q1 2025.
Clinic Revenue Strength (Greenbrook)
U.S. clinic revenue of $21.5 million, up 15% year-over-year, driven by continued SPRAVATO growth and expansion of buy-and-bill.
NeuroStar System Sales Momentum
U.S. NeuroStar system revenue of $3.2 million, up 13% year-over-year; shipped 34 systems in the quarter, a ~10% increase versus prior year.
Improved Profitability Trends
Net loss narrowed to $10.8 million ($0.16 per share) from $12.7 million ($0.21) year-over-year; adjusted EBITDA improved to negative $6.6 million from negative $8.6 million, a $2.0 million improvement.
Operating Expense Reductions
Operating expenses were $25.1 million, a decrease of $1.6 million (≈6%) versus Q1 2025, driven primarily by SG&A efficiencies.
Better Operating Cash Performance
Operating cash use improved to $9.4 million in Q1 2026 from $17.0 million in Q1 2025, an improvement of $7.6 million year-over-year.
Planned Annualized Cost Savings
Actions taken in the quarter are expected to deliver annualized savings of approximately $2.5 million to $3.0 million, with net savings beginning in Q3 2026.
Strategic and Commercial Initiatives Underway
Pilots to expand NeuroStar go-to-market models (early positive feedback), investments in virtual/on-demand customer support, and clinic workflow/revenue-cycle efforts to drive utilization and collections.
Regulatory and Payer Tailwinds
Potential upside from COMPASS psilocybin therapy if approved (company positioned to deliver); UHC/Optum change allowing nurse practitioners to deliver TMS expands addressable coverage (~35 million covered lives).
DE:NRC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:NRC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | €1.67 | €1.74 | +4.20% |
Mar 17, 2026 | €1.16 | €1.33 | +14.63% |
Nov 04, 2025 | €2.40 | €2.02 | -15.87% |
Aug 05, 2025 | €3.65 | €3.46 | -5.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Neuronetics (DE:NRC) report earnings?
Neuronetics (DE:NRC) is schdueled to report earning on Aug 04, 2026, Before Open (Confirmed).
What is Neuronetics (DE:NRC) earnings time?
Neuronetics (DE:NRC) earnings time is at Aug 04, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Neuronetics stock?
The P/E ratio of Neuronetics is N/A.
What is DE:NRC EPS forecast?
DE:NRC EPS forecast for the fiscal quarter 2026 (Q2) is -0.11.